Best Immunotherapy Companies in India
The 32 best Immunotherapy companies in India in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Immuneel.
- The Business Research Company
- ResearchAndMarkets.com
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in India
| # | Company | Revenue | Disclosed funding | Last round | Revenue YoY | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Serum Institute of India Manufacturer of vaccines and immuno-biological drugs for infectious diseases | $1.3B FY2025 | — | 172 mo ago | -2% | 6,537 6,537 → 5,902 (-10%) | Cyrus Poonawalla Founder & Managing Director | — | 294 patents Development and manufacturing of lyophilized viral and bacterial polysaccharide vaccines. | — |
| 2 | Bharat Biotech Manufacturer of vaccines and bio-therapeutic products | $201M FY2025 | $14M | 77 mo ago | — | 20 | Suchitra Ella Co-Founder & Managing Director | 4 signals Capital raise · IPO · Hiring | 312 patents Vaccine formulation and delivery technologies, including nucleic acid, polysaccharide, and viral vaccines | — |
| 3 | Indian Immunologicals Manufacturer of animal and human vaccines | $179M FY2025 | — | — | +8% | 1,752 | — | 3 signals Regulatory | 29 patents Vaccine manufacturing, toxoid purification, virus-like particle design, recombinant antibody therapeutics | — |
| 4 | Bio-Med Manufacturer of vaccines for human and animal use | $11M FY2025 | — | — | +19% | 175 | SP Garg Founder & MD | — | — | — |
| 5 | ImmunoACT Developer of cell and gene therapies for cancer treatment | $8M FY2025 | $16M | 41 mo ago | +510% | 139 139 → 193 (+39%) | Atharva Karulkar Co-Founder | — | — | — |
| 6 | PopVax Developer of mRNA platform for vaccines and therapeutics 74Growth top 18%Moat top 28%Tech top 31%Fin. health top 36% All 11 signals ▾Growthtop 18% Moattop 28% Techtop 31% Fin. healthtop 36% Patentstop 39% Fundingtop 42% Innovationtop 45% AItop 45% Markettop 46% Talentbottom 49% Globalbottom 37% Growth: Headcount 24 → 50 (+108%) across vintages · Revenue +45% YoY Moat: Top 14% by revenue among 42 tracked Infectious Diseases companies · Editorial + unicorn rating 3/10 rank vs industry peers · Fliar Intelligence Index 74/100 | $7M FY2025 | $6M | 13 mo ago | +45% | 50 50 → 79 (+58%) | Soham Sankaran Founder & CEO & Managing Director | — | 22 patents Multisubunit viral vaccines and lipid nanoparticle delivery platforms for nucleic acid therapeutics | — |
| 7 | Dano Vaccines Manufacturer of vaccines and biologicals committed to global public health | $4M FY2025 | $25K | 234 mo ago | +3% | 100 | D Raju Founder & Managing Director | — | — | — |
| 8 | Curadev Pharma Developer of small molecule immunotherapy drugs for cancer and inflammation | $2M FY2025 | $881K | 174 mo ago | +24% | 38 38 → 42 (+11%) | Arjun Surya Founder | — | 87 patents Small‑molecule STING antagonists and ACSS2 inhibitors for immuno‑modulation | — |
| 9 | Immuneel Developer of T-cell therapies for the treatment of cancer 40Moat top 31%Funding top 40%Growth top 46%Market top 49% All 9 signals ▾Moattop 31% Fundingtop 40% Growthtop 46% Markettop 49% Talentbottom 49% Fin. healthbottom 44% Globalbottom 39% Techbottom 31% Newsbottom 18% Moat: Top 21% by revenue among 34 tracked Oncology companies · Editorial + unicorn rating 7/10 Funding: Raised $39.3M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $1M FY2025 | $39M | 28 mo ago | +342% | 67 67 → 112 (+67%) | Siddhartha Mukherjee Co-Founder | — | — | — |
| 10 | CuraTeQ Biologics Developer of immuno-oncology therapeutics | $1M FY2025 | — | — | — | 535 535 → 668 (+25%) | Satakarni Makkapati CEO | 3 signals ▼57% Contracts | 4 patents Immunoassays detecting C1q binding for complement system diagnostics. | — |
| 11 | Zumutor Developer of novel immunotherapy and monoclonal antibody therapeutics 22Innovation top 34%Product top 36%Funding top 42%Tech top 50% All 10 signals ▾Innovationtop 34% Producttop 36% Fundingtop 42% Techtop 50% Globalbottom 43% Moatbottom 40% Growthbottom 33% Marketbottom 29% Newsbottom 27% Fin. healthbottom 16% Innovation: 4 product lines Product: 4 distinct product lines · Company stage: Series A rank vs industry peers · Fliar Intelligence Index 22/100 | $547K FY2025 | $26M | 23 mo ago | -64% | 24 24 → 25 (+4%) | — | — | — | — |
| 12 | Ricaptos Developer of drugs for oncology, cardiovascular, gastroenterology disease, and infectious diseases | $488K FY2025 | — | — | -17% | — | Gururaj R Founder & CEO | — | — | — |
| 13 | Invictus Oncology Developer of chemotherapeutics conjugated with antibodies for the treatment of cancer | $339K FY2025 | $7M | 120 mo ago | +20% | 38 | Raghunath Mashelkar Co-Founder | — | 51 patents Lipid‑nanoparticle delivery of platinum anticancer agents and signaling pathway inhibitor therapeutics | — |
| 14 | APAC Biotech Developer of autologous monocyte-derived dendritic cell immunotherapy for cancer | $155K FY2025 | $991K | 187 mo ago | -34% | — | Arun Mehra CEO & MD | — | — | — |
| 15 | Saksin Life Biologics and biosimilars for wet AMD & other eye diseases | $150K FY2021 | $1M | 100 mo ago | — | 1 | Mahesh Pratapneni Co-Founder | — | — | — |
Top 12 Immunotherapy companies in India
#1
Series A · Noida, Uttar Pradesh · founded 2021$1.9Mraised▾
Developer of cellular engineering methods and gene therapy based treatments. Research focuses on creating therapies for hematological malignancies, solid tumors, and blood disorders. Activities include the design of antigen targeting therapies and the application of gene editing techniques to modify hematopoietic stem cells. These approaches aim to address the underlying causes of inherited and metabolic conditions through cellular manipulation.
- May 2026Series A$2M
- Apr 2025Seed$885.6K
- Jan 2024Seed$1.8M
#2
Series A · Bengaluru, Karnataka · founded 2013 · 24 employees$26.2Mraised▾
Developer of novel immunotherapy and monoclonal antibody therapeutics. This company utilizes a proprietary human antibody platform to identify and develop first-in-class therapeutic antibodies. These antibodies target innate immunity and modulate the tumor microenvironment, focusing on targeted NK cell therapeutics within the immuno-oncology field. The company's approach centers on a platform for developing improved monoclonal antibody therapeutics. They maintain a commitment to scientific talent development within therapeutic research and development.
- Nov 2024Series A$730.4K
- Feb 2024Series A$720.3K
- Oct 2022Series A$241.3K
- Aug 2021Series A$6.2M
#3
Funding Raised · Hyderabad, Telangana · founded 2021 · 50 employees$5.6Mraised▾
Developer of mRNA platform for vaccines and therapeutics. It offers an open-source next-generation COVID-19 vaccine intended to broaden protection against both current and predicted future SARS-CoV-2 variants. It has a lipid nanoparticle (LNP) delivery platform for mRNA using PopVax-designed novel ionizable lipids and a machine learning-enabled computational approach.
- Sep 2025Grant (prize money)$3.6M
- Jan 2025Grant (prize money)$2M
#4
Series A · Bengaluru, Karnataka · founded 2018 · 67 employees$39.3Mraised▾
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells. It has developed CAR-T cell therapy extracted from patient's blood cells to target cancerous cells. The product pipeline includes IMN-003A, IMN-001, and IMN-002 for leukemias and lymphomas.
- Jun 2024Series A$12M
- Apr 2022Series A$15M
- Sep 2020Series A$1.4M
- Nov 2019Series A$11M
#5
Seed · Hyderabad, Telangana · founded 2024$1.5Mraised▾
Developer of vaccine targeting fat metabolism and stem cell therapies. The company focuses on creating immunotherapies to address the causes of chronic illnesses. It develops a vaccine targeting fat metabolism. Additionally, the company formulates stem cell-based therapies to support regenerative healing across multiple therapeutic areas.
- Jun 2025Seed$1.5M
#6
Series B · Mumbai, Maharashtra · founded 2018 · 139 employees$15.9Mraised▾
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia. It offers other pipeline products which include Actalycabtagene autoleucel for B-lymphoid malignancies, HCAR2 for multiple myeloma, and HCAr3 for Glioblastoma multiforme, and neuroblastoma.
- May 2023Series B$9.7M
- Nov 2021Series A$6.2M
- Oct 2021Seed—
- Oct 2020Seed—
#7
Early Stage · Hyderabad, Telangana · founded 1996 · 20 employees$13.7Mraised▾
Manufacturer of vaccines and bio-therapeutic products. It offers a portfolio of products which includes a broad range of vaccines and therapeutics for Hepatitis B, Polio, Rabies, Typhoid, tetanus, pertussis,, and Haemophilus influenzae type b. It also provide topical medicines for wounds, burns, ulcers, and others.
- Jun 2020Grant (prize money)—
- Jun 2015Grant (prize money)$18.5M
- May 2010Grant (prize money)$64.3K
- 2007PE$6M
#8
Seed · Bengaluru, Karnataka · founded 2021 · 3 employees$1.5Mraised▾
Developer of NK cell therapies for the treatment of cancer
- Oct 2023Seed$745.2K
- Apr 2023Grant (prize money)—
- Apr 2023Seed$622.2K
- Dec 2022Seed$778.3K
#9
Series A · Delhi, Delhi · founded 2011 · 38 employees$7Mraised▾
Developer of chemotherapeutics conjugated with antibodies for the treatment of cancer. The product pipeline has applications in the treatment of several types of cancer, including lung, testicular, colorectal, and childhood cancers. The portfolio includes platinum-based drugs that are engineered using structure-activity relationships and antibody-drug conjugates(ADC) for tumour-specific drug delivery.
- Oct 2016Series A$552.9K
- Jun 2016Series A$516.4K
- Apr 2016Series A—
- Aug 2015Series A$2.3M
#10
Seed · Chennai, Tamil Nadu · founded 2014 · 1 employees$1.4Mraised▾
Saksin Life is an Indian preclinical stage biopharma developing biologics and biosimilars for wet AMD & other eye diseases. Their lead candidate is a Monoclonal Antibody for Wet AMD, currently in preclinical studies.
- Jun 2018Seed$488K
- Jun 2017Seed$930.2K
#11
Seed · Gurugram, Haryana · founded 2010$991.2Kraised▾
Developer of autologous monocyte-derived dendritic cell immunotherapy for cancer. Its therapy named Apceden is an autologous (self) monocyte-derived DC immunotherapy which used the patient's own MAbs against cancer-specific dendritic cells. It has developed Apceden treatment for colorectal cancer, Non-small cell lung carcinoma, ovarian carcinoma, and prostate cancer and also developing for glioblastoma multiforme (GBM), and Renal cancer.
- Mar 2011Seed$991.2K
#12
Seed · Noida, Uttar Pradesh · founded 2010 · 38 employees$881.1Kraised▾
Curadev is a drug discovery company that provides R&D services to its clients along with working on its own programs. The company had licensed first in class dual IDO/TDO inhibitors patents to Roche, which are enzymes that mediate cancer-induced immune suppression. This mechanism is exploited by tumor cells as well as certain type of immune cells, limiting the anti-tumor immune response. Its had field 8 patent, for solid tumors, liquid tumors, breast cancer, and inflammation, investigational new drug (IND) application, and others.
- Apr 2012Grant (prize money)—
- Mar 2011Angel$881.1K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in India
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,737 India-affiliated papers.
- Ministry of Education188
- Cancer Institute110
- All India Institute of Medical Sciences63
- Saveetha University36
- Chitkara University35
- Immune system2→150
- Cancer immunotherapy1→58
- Cancer2→54
- Cancer research2→32
- Hepatocellular carcinoma1→9
- Immune system5→335
- Cancer immunotherapy2→98
- Tumor microenvironment2→95
- Internal medicine1→64
- Clinical trial1→57
- Cancer2→73
- Oncology2→29
- Clinical trial1→25
- Cancer immunotherapy2→25
- Tumor microenvironment1→22
Where immunology is researched across India
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in India
India immunology patent filing is accelerating — 49 filings from 115 assignees (2016–2025), led by Microcrispr, Serum Institute Of India, UNIV Louisiana State; annual filings 1→11.
- Microcrispr12
- Serum Institute Of India9
- UNIV Louisiana State9
- Genkyotex8
- CSIR6
- Giordano Anthony5
- Yerande Swapnil G5
- Inamdar Gajanan S5
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.